BSX vs MDT: Which Is the Better Buy in 2026?
Last updated October 2026
Short answer
MDT is the larger of the two ($121.20B market cap): the incumbent the market prices for continued execution (14.78x forward earnings, beta 0.57). BSX is the smaller challenger ($64.33B), priced similarly on forward earnings (13.15x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.
BSX vs MDT: the tie-breaker metrics
Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | BSX | MDT | What it tells you |
|---|---|---|---|
| Market cap | $64.33B | $121.20B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 13.15 | 14.78 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Trailing P/E | 17.97 | 23.28 | Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price. |
| Beta | 0.57 | 0.57 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 5% of range | 65% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 2.58 | 2.41 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Before you buy: how BSX and MDT affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BSX and MDT share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BSX and MDT exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Boston Scientific Corporation (BSX) do?
Boston Scientific Corporation is a Marlborough, Massachusetts-based medical device company that develops, manufactures, and markets minimally invasive devices used in interventional cardiology, electrophysiology, structural heart, peripheral interventions, endoscopy, urology, neuromodulation, and cardiac rhythm management. It reports through two broad segments: Cardiovascular, which houses the electrophysiology business (led by the Farapulse pulsed field ablation system) and the Watchman left-atrial-appendage closure franchise, and MedSurg, which spans endoscopy, urology, and neuromodulation. The company sells into hospitals and physicians across roughly 130 countries and competes at the leading edge of catheter-based and device-based procedures that substitute for more invasive surgery.
What does Medtronic (MDT) do?
Medtronic is one of the largest medical device companies in the world, designing, manufacturing, and selling therapies and devices across a broad range of chronic and acute conditions. Its business spans three main areas after October 2026: Cardiovascular (pacemakers, defibrillators, heart valves, and cardiac ablation), Neuroscience (spine implants, neuromodulation for pain and movement disorders, and surgical navigation), and Medical Surgical (surgical stapling, energy devices, and a growing robotic-surgery platform). Its former Diabetes unit (insulin pumps and continuous glucose monitoring) was carved out as MiniMed, which listed on Nasdaq under MMED; on October 15, 2026 Medtronic exchanged its remaining 252.8 million MiniMed shares for Medtronic shares in an exchange offer that was 5.4 times subscribed, so it no longer owns any of MiniMed. The company sells primarily to hospitals, surgeons, and health systems, generating durable, recurring demand tied to procedure volumes and chronic-disease management. Medtronic's scale gives it deep relationships with providers, a large installed base of devices, and the resources to fund extensive R&D and acquisitions. Growth depends on new product cycles, pipeline approvals, and global expansion, especially in emerging markets. Founded in 1949 and headquartered in Ireland for tax purposes (operationally rooted in Minnesota), Medtronic is a large-cap, dividend-growing medical-technology company tied to long-term healthcare demand and aging demographics, with trailing revenue of about $37.5 billion as of October 2026.
BSX vs MDT: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- BSX drivers: Farapulse and the Pulsed Field Ablation Wave; Watchman Franchise Expansion.
- MDT drivers: Diversified device portfolio; Innovation pipeline and new product cycles.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The most immediate concern is a run of setbacks in 2026. For MDT, medtronic has at times delivered sluggish organic growth, raising concerns that its scale slows innovation relative to nimbler competitors like Boston Scientific and Edwards Lifesciences.
BSX or MDT: which should you pick?
Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick BSX if you believe its drivers more; MDT if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BSX and MDT guides.
BSX vs MDT: the full fundamentals
BSX. Boston Scientific's trailing P/E of roughly 18x and forward multiple near 13x are far below the sustained premium the stock carried during its high-growth phase. The compression followed a decline of about 55% over the past year, while the S&P 500 rose about 17%, driven by slowing growth, repeated outlook cuts, and the September cybersecurity disruption. Third-quarter results are due October 28, 2026, with consensus near $0.74 to $0.76 of adjusted EPS on revenue of about $5.1 billion, and the analyst mean target of about $59 sits well above the $44.06 share price, so the debate is whether the lower multiple reflects fair concern about decelerating growth or an over-correction.
MDT. At about $95 on October 16, 2026, Medtronic trades near 15 times forward earnings, a moderate multiple next to faster-growing medtech peers, while the GAAP trailing P/E of about 23x includes acquisition amortization. The 25 analysts tracked by Yahoo Finance hold a mean target near $104. The next report, expected around November 17, 2026, will be the first read on the company after the MiniMed exit, with consensus at about $1.33 of EPS on $9.5 billion of revenue.
Headline figures (approximate, October 2026): BSX shows revenue (ttm) ~$21 billion (+7.5% YoY in Q2 2026), revenue (fy 2025) ~$20.1 billion, net income (ttm) ~$3.7 billion (profit margin ~17.5%), adjusted eps (q2 2026) $0.86 vs $0.83 est.; MDT shows revenue (ttm) ~$37.5 billion, up ~14% year over year in the July 2026 quarter, margins ~65% gross, ~19% operating, ~14% net, net income (ttm) ~$5.2 billion, eps ~$4.07 GAAP trailing; ~$6.41 forward estimate.
The bottom line: BSX vs MDT
BSX and MDT are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined BSX and MDT exposure against your real portfolio. It is not an investment adviser.
Wondering how BSX or MDT fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Investing in Boston Scientific Corporation with AI
Connect the broker you already use and ask Walnut's AI how BSX fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
What is the difference between BSX and MDT?
+
Boston Scientific Corporation is a Marlborough, Massachusetts-based medical device company that develops, manufactures, and markets minimally invasive devices used in interventional cardiology, electrophysiology, structural heart, peripheral interventions, endoscopy, urology, neuromodulation, and cardiac rhythm management. Medtronic is one of the largest medical device companies in the world, designing, manufacturing, and selling therapies and devices across a broad range of chronic and acute conditions. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is BSX or MDT the better stock?
+
Neither is universally better. MDT is the larger incumbent; BSX is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, BSX or MDT?
+
On forward P/E (as of October 2026), BSX trades at 13.15x and MDT at 14.78x, so BSX is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both BSX and MDT?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of BSX vs MDT?
+
BSX: The most immediate concern is a run of setbacks in 2026. Management lowered its profit outlook in July on weaker Watchman demand and US electrophysiology share losses, then in September said a cybersecurity incident had disrupted manufacturing and order shipments and that it was unlikely to meet its third-quarter and full-year sales and adjusted earnings forecasts. In October it recalled 262,686 Imager II angiographic catheters because the tip may fracture or detach during use, a reminder of the product-recall and safety-signal risk inherent to medical devices. Competition is intensifying as Medtronic and Johnson and Johnson scale their own pulsed field ablation systems, which could further erode Boston Scientific's early PFA share and pressure pricing. Brokers including Baird, Truist and Mizuho trimmed price targets in mid-October 2026. Foreign exchange swings, hospital capital-spending cycles, reimbursement or regulatory changes, about $12.6 billion of debt, and integration risk from the company's acquisition strategy each add uncertainty. MDT: Medtronic has at times delivered sluggish organic growth, raising concerns that its scale slows innovation relative to nimbler competitors like Boston Scientific and Edwards Lifesciences. The Hugo robotic platform faces an entrenched Intuitive Surgical. The MiniMed separation removes diabetes but adds near-term noise: reported results, guidance and comparisons will shift as the unit leaves the numbers, and analysts expect EPS of about $1.33 for the quarter ending October 2026, slightly below the year-earlier level. Device companies face reimbursement pressure, hospital budget constraints, FDA approval and recall risk, and litigation exposure. A large international footprint brings currency headwinds, and debt stood near $28 billion against about $8.8 billion of cash as of October 2026. The stock is roughly flat over the past year despite faster sales growth. New-product execution, pipeline timing, and the ability to sustain organic growth remain the key swing factors for the investment case.
Related comparisons
Browse all stock comparisons.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell BSX or MDT; figures are approximate and dated (as of October 2026). Verify current data before investing.